Salarius Pharmaceuticals, Inc. - SLRX STOCK NEWS

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that three research abstracts on seclidemstat have been accepted for presentations at the 2021 ASCO Annual Meeting from June 4-8, 2021. One of these abstracts will be featured in a poster discussion session. The findings from the ongoing Phase 1/2 trial of seclidemstat in relapsed Ewing sarcoma will be detailed at the conference. Seclidemstat is being developed as a treatment for pediatric and other cancers with significant unmet needs, and has received multiple designations from the FDA.

Salarius Pharmaceuticals (Nasdaq: SLRX) reported its year-end results for 2020, highlighting significant progress in developing its LSD1 inhibitor, seclidemstat, for treating Ewing sarcoma and other cancers. The company completed the dose-escalation stage of its Phase 1/2 trial and established a recommended Phase 2 dose. Financially, Salarius is well-capitalized with approximately $37 million in cash from recent offerings. The net loss per share significantly decreased to $0.10 in Q4 2020 from $0.46 in Q4 2019, while the full-year loss was $0.50 compared to $2.12 in 2019.

Salarius Pharmaceuticals (SLRX) will host a conference call on March 18, 2021, at 4:30 p.m. ET to discuss its Q4 2020 and full year 2020 financial results. The company, focused on developing treatments for pediatric cancers, has its lead candidate, seclidemstat, in a Phase 1/2 trial for Ewing sarcoma, having received several designations from the FDA aimed at expediting its development. The call details include U.S. and international dial-in numbers, with a webcast available on the company’s investor site.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced the closing of its public offering of 16,806,722 shares at $1.3685 per share, generating approximately $23 million in gross proceeds. This financing boosts Salarius' cash availability to around $37 million, sufficient to support ongoing clinical trials for its lead drug candidate, seclidemstat. The funding aims to enhance treatment for Ewing sarcoma and other cancers. Delivery of clinical trial data is anticipated in June 2021, presenting potential regulatory pathways and commercial opportunities.

Salarius Pharmaceuticals (SLRX) announced a public offering of 14,614,541 shares at $1.3685 each, aiming to raise approximately $20 million, with closing expected around March 8, 2021. The offering includes a 45-day option for underwriters to purchase an additional 2,192,181 shares. Ladenburg Thalmann is the book-running manager for this offering. The proceeds will support Salarius's clinical programs, including trials for its lead candidate, seclidemstat, a potential treatment for pediatric cancers and solid tumors.

Salarius Pharmaceuticals (Nasdaq: SLRX) has announced the commencement of an underwritten public offering of its common stock. The offering is subject to market conditions, and details regarding its size and terms remain undetermined. Ladenburg Thalmann & Co. Inc. is the sole book-running manager for this offering. The company has a registered shelf statement with the SEC, allowing for the sale of shares. Salarius focuses on developing new cancer therapies, particularly for pediatric and other challenging cancers, with its lead candidate currently undergoing clinical trials.

Salarius Pharmaceuticals (Nasdaq: SLRX) has initiated the expansion stage of its Phase 1/2 clinical trial for seclidemstat, targeting relapsed and refractory Ewing sarcoma patients. This phase includes two arms: combining seclidemstat with topotecan and cyclophosphamide for Ewing sarcoma, and using it as a single-agent therapy for Ewing-related sarcomas. Preliminary results show extended time to progression, with data readouts expected by the end of 2021 into 2022. The company aims to enhance treatment options for patients with limited alternatives.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Diamond Equity Research Emerging Growth Invitational Conference on February 24, 2021. The presentation will cover Salarius’ business overview, recent achievements, and upcoming clinical milestones for seclidemstat, a reversible LSD1 inhibitor currently in Phase 1/2 trials for Ewing sarcoma and advanced solid tumors. Attendees can participate in a Q&A session. A recording will be available post-event on the company’s investor page.

Salarius Pharmaceuticals has established the recommended Phase 2 dose (RP2D) for its seclidemstat in a Phase 1/2 trial focused on relapsed/refractory Ewing sarcoma. Data from the trial showcased a manageable safety profile and preliminary signs of drug activity, particularly in Ewing-related sarcoma patients. Encouraging results indicated over 75% tumor shrinkage in a refractory patient. The trial plans to expand to treat more patients and present full findings at a medical conference. Further data readouts are expected by the end of this year and early next year.